CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
Subscribe To Our Newsletter & Stay Updated
